Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | REGN15505 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on REGN15505, a bispecific antibody targeting FOLH1 (PSMA) and TNFRSF9 (4-1BB) (Aug 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| REGN15505 | REGN 15505|REGN-15505 | PSMA Antibody 25 TNFRSF9 Antibody 37 | Limited information is currently available on REGN15505, a bispecific antibody targeting FOLH1 (PSMA) and TNFRSF9 (4-1BB) (Aug 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07594106 | Phase Ib/II | REGN15505 + REGN4336 Cemiplimab + REGN15505 REGN15505 | REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma | Recruiting | USA | 0 |